Orchid Pharma Ratios

Orchid Pharma Ltd Ratios

The Orchid Pharma Ltd Ratios page provides a complete fundamental analysis of Orchid Pharma Ltd using key valuation, profitability, and financial strength metrics. Investors tracking Orchid Pharma Ltd Ratios closely monitor D/E, EV, EV/EBITDA, P/B, P/CF, P/E, P/S, and ROE% to evaluate the company's financial performance and valuation trends over time.

Orchid Pharma Ltd (NSE: ORCHPHARMA, BSE: 524372) is currently trading at ₹545.30, with a market capitalization of ₹28.94B. As a major player in the Health technology sector and Pharmaceuticals: major industry, Orchid Pharma Ltd remains a key stock for fundamental analysis using Orchid Pharma Ltd Ratios.

Orchid Pharma Ltd Ratios: Valuation Overview

Price to Earnings Ratio (P/E)

The Orchid Pharma Ltd P/E ratio currently stands at 39.54, making it one of the most tracked metrics in Orchid Pharma Ltd Ratios.

Historically, the Orchid Pharma Ltd P/E ratio has shown strong fluctuations:

• 2024: 39.54
• 2023: 54.85
• 2022: 33.87
• 2021: 0
• 2020: 0

The decline in Orchid Pharma Ltd P/E ratio suggests improving earnings relative to stock price.

Price to Book Ratio (P/B)

The Orchid Pharma Ltd P/B ratio reflects how the market values the company's net assets. Current P/B ratio is 3.29.

Historical P/B trend:

• 2024: 3.29
• 2023: 4.82
• 2022: 2.53
• 2021: 2

Orchid Pharma Ltd is trading at a premium to its book value, indicating strong market confidence.

Price to Sales Ratio (P/S)

The Orchid Pharma Ltd P/S ratio currently stands at 4.29, an important part of Orchid Pharma Ltd Ratios for revenue valuation.

Historical P/S ratio:

• 2024: 4.29
• 2023: 6.17
• 2022: 2.36
• 2021: 2.07

A stable or declining Orchid Pharma Ltd P/S ratio indicates cautious market sentiment.

Orchid Pharma Ltd Price to Cash Flow Ratio (P/CF)

The Orchid Pharma Ltd Price to Cash Flow Ratio is a key valuation metric that shows how much investors pay for each unit of cash flow. Current P/CF ratio is 113.10.

Historical Orchid Pharma Ltd Price to Cash Flow Ratio:

• 2024: 113.10
• 2023: 41.56
• 2022: 0
• 2021: 19.04
• 2020: 0

The rising Orchid Pharma Ltd Price to Cash Flow Ratio indicates premium valuation based on cash flow.

Orchid Pharma Ltd Enterprise Value Ratios

Enterprise Value (EV)

The Orchid Pharma Ltd EV currently stands at ₹40.04B, representing the total company valuation including debt.

Historical EV trend:

• 2024: 40.04B
• 2023: 49.92B
• 2022: 19.38B
• 2021: 14.89B

Orchid Pharma Ltd enterprise value consolidation suggests stable valuation.

EV/EBITDA Ratio

The Orchid Pharma Ltd EV/EBITDA ratio is currently 34.62, a key metric in Orchid Pharma Ltd Ratios to assess valuation relative to earnings.

Historical EV/EBITDA:

• 2024: 34.62
• 2023: 45
• 2022: 22.95
• 2021: 27.28

Stable Orchid Pharma Ltd EV/EBITDA indicates balanced valuation.

Orchid Pharma Ltd Financial Strength Ratios

Debt to Equity Ratio (D/E)

The Orchid Pharma Ltd D/E ratio is currently 0.20, reflecting leverage and financial stability.

Historical D/E:

• 2024: 0.20
• 2023: 0.19
• 2022: 0.64
• 2021: 0.58

Orchid Pharma Ltd maintains a strong balance sheet with low debt levels.

Return on Equity (ROE %)

The Orchid Pharma Ltd ROE currently stands at 8.67%, showing profitability and capital efficiency.

Historical ROE:

• 2024: 8.67
• 2023: 10.71
• 2022: 8.86
• 2021: -10.39

Declining ROE indicates pressure on profitability.

Orchid Pharma Ltd Ratios Analysis Summary

The Orchid Pharma Ltd Ratios page provides a comprehensive view of the company's valuation and financial performance. Key metrics such as P/E, P/B, P/S, P/CF, EV, EV/EBITDA, D/E, and ROE help investors understand whether Orchid Pharma Ltd stock is undervalued, fairly valued, or overvalued.

Tracking Orchid Pharma Ltd Ratios regularly helps investors make informed decisions based on valuation trends, financial stability, and long-term growth potential.